Shares of Tocagen Inc (NASDAQ:TOCA) have received an average broker rating score of 2.00 (Buy) from the two brokers that cover the company, Zacks Investment Research reports. One research analyst has rated the stock with a hold rating and one has given a strong buy rating to the company.
Brokerages have set a 12-month consensus target price of $23.67 for the company and are expecting that the company will post ($0.53) EPS for the current quarter, according to Zacks. Zacks has also assigned Tocagen an industry rank of 196 out of 265 based on the ratings given to related companies.
Several research analysts recently weighed in on TOCA shares. BidaskClub upgraded shares of Tocagen from a “hold” rating to a “buy” rating in a research report on Tuesday. Zacks Investment Research upgraded shares of Tocagen from a “sell” rating to a “hold” rating in a research report on Wednesday, October 11th.
Tocagen (NASDAQ:TOCA) traded down $0.88 on Friday, hitting $13.51. 99,385 shares of the company traded hands, compared to its average volume of 227,710. Tocagen has a 52-week low of $8.60 and a 52-week high of $17.95. The company has a debt-to-equity ratio of 0.07, a quick ratio of 6.03 and a current ratio of 6.03. The firm has a market cap of $267.63 and a P/E ratio of -6.76.
Tocagen (NASDAQ:TOCA) last released its quarterly earnings results on Wednesday, November 8th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.02). The company had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.01 million. sell-side analysts expect that Tocagen will post -2.66 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: “Brokerages Anticipate Tocagen Inc (TOCA) to Post ($0.53) EPS” was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this piece on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2018/01/27/brokerages-anticipate-tocagen-inc-toca-to-post-0-53-eps.html.
Tocagen Inc (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.